Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk
Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk
复制标题
DOI：
10.1002/ijc.11230
复制
发表时间：
2003-09-01
影响因子：
6.4
通讯作者：
Feychting, M
中科院分区：
文献类型：
--
作者：
Schwartzbaum, J;Jonsson, F;Feychting, M
先前在病例对照研究中观察到，自我报告的过敏与神经胶质瘤和脑膜瘤风险之间存在负相关。然而，这些研究中大约 27%（中位数）的神经胶质瘤和脑膜瘤信息是从代理受访者那里收集的。事实上，以往脑肿瘤研究中的比值比 (OR) 与代理受访者的比例成反比（Pearson 相关系数 = -0.94；95% Cl = -1.00 至 -0.65）；这种相关性表明存在偏见。因此，我们根据瑞典双胞胎、医院出院和癌症登记处构建了 3 个队列。在队列 I（14,535 人患有 37 种神经胶质瘤和 41 种脑膜瘤）和 11 组（29,573 人患有 42 种神经胶质瘤和 26 种脑膜瘤）中，从过敏自我报告到脑肿瘤诊断的中位时间为 15.4 年。第 III 组与第 I 组和第 11 组（52,067 人患有 68 种神经胶质瘤和 63 种脑膜瘤）重叠，与瑞典医院出院登记处相关，该登记处记录了脑肿瘤免疫相关出院诊断。在队列 I（风险比 [HR] = 0.45；95% Cl = 0.19-1.07）和高级别（III 和 IV，HR = 0.45；95% Cl = 0.11-1.92）中，过敏与神经胶质瘤风险呈负相关，但低级别（I 和 11，HR = 2.60，95% Cl = 0.86-7.81）队列 11 中的神经胶质瘤。在队列 III 中，免疫相关的出院诊断也与神经胶质瘤呈负相关（HR = 0.46；95% Cl = 0.14-1.49）。没有强有力的证据反对（有些支持）过敏会降低神经胶质瘤风险的假设。 (C) 2003 Wiley-Liss, Inc.
An inverse association between self-reported allergies and glioma and meningioma risk, has been previously observed in case-control studies. Approximately 27% (median) of the information on both glioma and meningioma in these studies, however, is collected from proxy respondents. In fact, the odds ratios (OR) among previous brain tumor studies are inversely related to the proportion of proxy respondents (Pearson correlation coefficient = -0.94; 95% Cl = -1.00 to -0.65); this correlation suggests bias. We therefore constructed 3 cohorts based on the Swedish Twin, Hospital Discharge, and Cancer Registries. In Cohorts I (14,535 people developed 37 gliomas and 41 meningiomas) and 11 (29,573 people developed 42 gliomas and 26 meningiomas) median time from self-report of allergies to brain tumor diagnosis was 15.4 years. Cohort III, which overlaps with Cohorts I and 11 (52,067 people developed 68 gliomas and 63 meningiomas), was linked to the Swedish Hospital Discharge Registry where pre-brain tumor immune-related discharge diagnoses were recorded. Allergies are inversely associated with glioma risk in Cohort I (Hazard ratio [HR] = 0.45; 95% Cl = 0.19-1.07) and among high grade (III and IV, HR = 0.45; 95% Cl = 0.11-1.92) but not low grade (I and 11, HR = 2.60, 95% Cl = 0.86-7.81) gliomas in Cohort 11. In Cohort III, immune-related discharge diagnoses are also inversely associated with glioma (HR = 0.46; 95% Cl = 0.14-1.49). There is no strong evidence against (and some for) the hypothesis that allergies reduce glioma risk. (C) 2003 Wiley-Liss, Inc.